HRP20171908T1 - Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora - Google Patents

Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora Download PDF

Info

Publication number
HRP20171908T1
HRP20171908T1 HRP20171908TT HRP20171908T HRP20171908T1 HR P20171908 T1 HRP20171908 T1 HR P20171908T1 HR P20171908T T HRP20171908T T HR P20171908TT HR P20171908 T HRP20171908 T HR P20171908T HR P20171908 T1 HRP20171908 T1 HR P20171908T1
Authority
HR
Croatia
Prior art keywords
receptor ligands
pharmaceutical preparation
methods used
treatment methods
preparation containing
Prior art date
Application number
HRP20171908TT
Other languages
English (en)
Inventor
Nika Adham
Gary Samoriski
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of HRP20171908T1 publication Critical patent/HRP20171908T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (2)

1. Trans-4-{2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin i njegove farmaceutski prihvatljive soli za upotrebu u liječenju glavnih depresivnih poremećaja.
2. Trans-4-{2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za upotrebu prema zahtjevu 1, naznačen time da je u obliku trans-4-{2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin hidroklorida.
HRP20171908TT 2007-08-03 2008-08-04 Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora HRP20171908T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95369407P 2007-08-03 2007-08-03
EP08782602.0A EP2185155B1 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
PCT/US2008/072066 WO2009020897A1 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands

Publications (1)

Publication Number Publication Date
HRP20171908T1 true HRP20171908T1 (hr) 2018-01-26

Family

ID=40338740

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171908TT HRP20171908T1 (hr) 2007-08-03 2008-08-04 Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora

Country Status (20)

Country Link
US (3) US20090036468A1 (hr)
EP (1) EP2185155B1 (hr)
JP (1) JP5460594B2 (hr)
KR (1) KR101612563B1 (hr)
CN (1) CN101815519B (hr)
AU (1) AU2008283989B2 (hr)
CA (1) CA2695519A1 (hr)
CY (1) CY1119828T1 (hr)
DK (1) DK2185155T3 (hr)
EA (1) EA018064B1 (hr)
ES (1) ES2653852T3 (hr)
HR (1) HRP20171908T1 (hr)
HU (1) HUE036004T2 (hr)
LT (1) LT2185155T (hr)
MY (1) MY157192A (hr)
NO (1) NO2185155T3 (hr)
PL (1) PL2185155T3 (hr)
PT (1) PT2185155T (hr)
SI (1) SI2185155T1 (hr)
WO (1) WO2009020897A1 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730287C (en) 2008-07-16 2017-02-07 Forest Laboratories Holdings Limited Pharmaceutical formulations containing dopamine receptor ligands
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
MX353209B (es) * 2010-06-18 2018-01-08 Altos Therapeutics Llc Antagonistas d2, metodos de sintesis y metodos de uso.
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) * 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
JP2022529476A (ja) 2019-04-17 2022-06-22 コンパス パスファインダー リミテッド 不安障害、頭痛障害、及び摂食障害をサイロシビンで治療するための方法
GEAP202416526A (en) * 2021-10-28 2024-09-25 Richter Gedeon Nyrt Treatment of major depressive disorder
JP2025500844A (ja) * 2021-12-13 2025-01-15 コンパス パスファインダー リミテッド 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤
JP2025509390A (ja) * 2022-03-17 2025-04-11 マピ ファーマ リミテッド カリプラジン又はその塩を含むデポシステム

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6556540B1 (en) * 1998-05-29 2003-04-29 Paradyne Corporation System and method for non-intrusive measurement of service quality in a communications network
DE19983836C1 (de) * 1999-10-25 2003-10-23 Lundbeck As Valby H Verfahren zur Herstellung von Citalopram, 4-[1-(4- Fluorphenyl)-methanoyl]-benzonitril-Derivate und Verfahren zu deren Herstellung und deren Verwendung
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
UA82828C2 (en) * 2001-05-01 2008-05-26 Lundbeck & Co As H The use of enantiomeric pure escitalopram for treatment of depression
AU2003235442A1 (en) * 2002-04-12 2003-10-27 Sepracor, Inc. 3-aza- and 1,4-diaza-bicyclo(4.3.0)nonanes, and methods of use thereof
ES2282632T3 (es) * 2002-06-20 2007-10-16 H. Lundbeck A/S Terapia de combinacion en la que se usa un inhibidor de la reabsorcion de serotonina.
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
KR20060072127A (ko) * 2003-09-04 2006-06-27 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 억제제 및 록사핀의 조합
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása

Also Published As

Publication number Publication date
NO2185155T3 (hr) 2018-03-03
AU2008283989A1 (en) 2009-02-12
EA201000280A1 (ru) 2010-08-30
EA018064B1 (ru) 2013-05-30
JP5460594B2 (ja) 2014-04-02
MY157192A (en) 2016-05-13
CN101815519B (zh) 2013-08-21
LT2185155T (lt) 2017-12-11
CA2695519A1 (en) 2009-02-12
CN101815519A (zh) 2010-08-25
EP2185155A4 (en) 2012-04-25
EP2185155B1 (en) 2017-10-04
PL2185155T3 (pl) 2018-03-30
DK2185155T3 (en) 2018-01-02
ES2653852T3 (es) 2018-02-09
CY1119828T1 (el) 2018-06-27
US20090036468A1 (en) 2009-02-05
PT2185155T (pt) 2018-01-04
KR101612563B1 (ko) 2016-04-14
US20110015208A1 (en) 2011-01-20
SI2185155T1 (en) 2018-02-28
JP2010535790A (ja) 2010-11-25
US20120028991A1 (en) 2012-02-02
HUE036004T2 (hu) 2018-06-28
KR20100059830A (ko) 2010-06-04
EP2185155A1 (en) 2010-05-19
HK1144784A1 (en) 2011-03-11
AU2008283989B2 (en) 2013-12-05
WO2009020897A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
HRP20171908T1 (hr) Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora
EA200971046A1 (ru) Новые соли пиперазина в качестве d/d-антагонистов
HRP20130059T1 (hr) Derivati indolinona za lijeäśenje ili prevenciju fibroznih bolesti
JP2011148799A5 (hr)
CY1119663T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
IN2014CN00408A (hr)
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
MX2019009564A (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida.
AR085650A1 (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y usos
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
JP2011524850A5 (hr)
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
ATE539750T1 (de) Trans-4-ä2-ä4-(2,3-dichlorophenyl)-piperazin-1- ylü-ethylü-n,n-dimethylcarbamoyl-cyclohexylamin zur behandlung von schizophrenie
CO2020000168A2 (es) Preparación sólida de cariprazina para administración oral
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP2012507535A5 (hr)
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
MX379558B (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida.
HRP20200662T1 (hr) Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak
DK2197841T3 (da) Guanidinholdige forbindelser anvendelige som muscariniske receptorantagonister
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
RU2015142383A (ru) Новейшие антагонисты trpa1-рецепторов
EA201692298A1 (ru) Производные карбоксамидов